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Chondroitin sulfate proteoglycan 4 (CSPG4) is a mem-
brane bound proteoglycan, composed of an N-linked
280kDa glycoprotein, and a single 450kDa chondroitin sul-
fate linked proteoglycan [1]. CSPG4 expression has been
documented on adult malignancies (melanoma, breast,
mesothelioma) but has yet to be assessed on pediatric
malignancies [2,3]. Furthermore, both monoclonal antibo-
dies and chimeric antigen receptor (CAR) T cells against
CSPG4 have shown modest anti-tumor efficacy in adult
malignancies [2,3]. We screened a spectrum of pediatric
solid tumor lines for CSPG4 expression to determine
potential targets, then developed CSPG4-redirected CARs
to target CSPG4+ pediatric solid tumors.
16 pediatric tumor lines were assessed for CSPG4
expression. CSPG4 was detected by flow cytometry in
69% of the cell lines assessed: osteosarcomas: 143b,
HOS-MNNG,MG63; synovial sarcomas: SYO-I,HSSY-II,
alveolar/embryonal rhabdomyosarcomas: Rh18c,Rh30/
Rh36, medulloblastoma: DAOY, melanoma: Mel624,
Mel1300. CSPG4 expression site density was estimated
with BD PE Quantibrite beads by flow cytometry.
Using two different single chain variable fragments
(scFv) known to target CSPG4 (225.28 and TP41.2), two
anti-CSPG4 second generation CAR constructs were
synthesized by transient transfection of retroviral packa-
ging lines. Both constructs have identical intracellular sig-
naling components (CD28, CD3z). Healthy donor T cells
were transduced with viral supernatants, and assessed for
CAR expression. Anti-tumor activity was measured by
cytokine release and tumor specific lysis. Cell surface
expression of the CSPG4-based CARs was detected by
flow cytometry using conjugated Protein L to target the
expressed scFv light chain. 225.28 and TP41.2 based CAR
T cells induced 25% and 31% lysis of target pediatric
tumor lines, respectively (E:T ratio of 20:1). On further
investigation, TP41.2 based CAR T cells were able to
specifically lyse CSPG+ cell lines 143b, Rh30, and Rh18c
at 40%, 37%, and 16%, respectively (E:T ratio of 30:1).
Additionally, the TP41.2 and 225.28 CAR T cells were
assessed for Interferon gamma (IFNy) production by flow
cytometry. Compared to mock T cells coincubated with
varying tumor lines (143b, Rh30, DND41), the TP41.2 and
225.28 CAR+ T cells had significantly positive populations
for IFNy production (p < 0.0001), predominantly in the
CD8+ population.
High levels of CSPG4 are present on a variety of pedia-
tric solid tumors. TP41.2 CSPG4-based CAR T cells target,
generate significant levels of IFNy, and lyse osteosarcoma
in vitro at significant levels (p = 0.01). Targeting CSPG4
with CAR redirected T cells represents a new strategy for
eliminating these pediatric malignancies in an antigen
specific, cell-mediated manner.
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